Drug Coated Balloon Catheter Market Size - Share Outlook, Growth Analysis Report and Forecast Trends 2026-2030

Drug-coated balloon catheters are designed to deliver antiproliferative drugs directly to vessel walls during angioplasty, preventing the tissue overgrowth that causes re-narrowing. Unlike drug-eluting stents, they leave no permanent implant behind, which appeals to both physicians and patients for certain lesion types. The market encompasses both coronary and peripheral vascular applications, with peripheral use representing the fastest expanding segment due to rising prevalence of peripheral artery disease globally.

• •Global market valued at approximately $1.64 billion in 2025
• •Projected compound annual growth rate of 11.04% through the early 2030s
• •Covers coronary and peripheral artery disease treatment applications

The primary catalyst for market expansion is the worldwide increase in cardiovascular and peripheral vascular diseases driven by sedentary lifestyles, diabetes, tobacco use, and aging demographics. Clinical evidence demonstrating lower restenosis rates compared to plain balloon angioplasty has driven physician adoption and expanded insurance coverage. Additionally, growing preference for minimally invasive alternatives to open surgical procedures and ongoing technological refinements in drug coating formulations are accelerating uptake across both developed and emerging markets.

• •Rising global prevalence of peripheral artery disease and coronary artery disease
• •Clinical superiority over plain balloon angioplasty in preventing vessel re-narrowing
• •Advantages of avoiding permanent stent implants in certain patient anatomies

The market bifurcates into coronary drug-coated balloons for heart artery interventions and peripheral drug-coated balloons for leg and other non-coronary vessels, with the peripheral segment growing at a notably faster pace. Geographically, North America commands the largest share due to high procedure volumes, favorable reimbursement policies, and early adoption of advanced technologies, while the Asia-Pacific region represents the most rapidly expanding market driven by improving healthcare infrastructure and growing disease awareness.

• •Peripheral applications outpacing coronary applications in growth rate
• •North America leads in market share, with Europe as the second-largest region
• •Asia-Pacific emerging as the fastest-growing regional market

What are the recent trends and outlook?

The market is moving toward more precise drug delivery systems with biodegradable coating technologies and paclitaxel-sparing formulations to address ongoing safety discussions. Increased focus on treating femoropopliteal and tibial lesions in peripheral artery disease is shifting product development priorities, while value-based reimbursement models are influencing adoption patterns. With the global aging trend and expanding indications, the market is expected to maintain double-digit growth through the forecast period as new entrants and innovations continue to emerge.

• •Development of next-generation coatings with improved safety and efficacy profiles
• •Growing emphasis on peripheral artery disease applications beyond coronary use
• •Continued double-digit growth trajectory expected through the early 2030s